SPR Technology for the Identification of New Therapeutic Agents from Phage Display Libraries

About this poster

In this work, we highlight how IRBM leverages Surface Plasmon Resonance (SPR) technology as a crucial part of the screening process for therapeutic peptides and monoclonal antibodies. SPR assays enable detailed analysis of binding kinetics and affinities for leads identified through phage display. This approach supports the selection and optimization of the most promising candidates, ensuring their suitability for further development in drug discovery programs.